<DOC>
	<DOCNO>NCT01713920</DOCNO>
	<brief_summary>A majority Korean doctor tend add antihypertensive rather titrate drug . However , try induce doctor titrate Sevikar add antihypertensive patient control Sevikar 5/20mg ( amlodipine 5mg + omlesartan 20mg ) . As , patient control Sevikar 5/20mg , doctor proceed prescription pattern choice titration Sevikar 5/40 , 10/40mg . It important evaluate BP lower efficacy Sevikar titration step patient uncontrolled Sevikar low dose . Thus , study design demonstrate efficacy Sevikar titration patient control BP low dose Sevikar .</brief_summary>
	<brief_title>Efficacy Tolerability Combination Antihypertensive Drug Non-Responders ARB monoTHerapy Using 24h ABPM</brief_title>
	<detailed_description />
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Male female subject &gt; 55 year 2 . Subject consent participate signing informed consent form 3 . Uncontrolled hypertensive patient define : Uncontrolled hypertensive : subject mean SBP ≥ 140 mmHg treat ARB ( Valsartan 80mg Candesartan 8mg ) monotherapy least 4 week . 1 . Secondary hypertension 2 . SeSBP ≥ 180mmHg 3 . SeSBP difference ≥ 20mmHg SeDBP difference ≥ 10mmHg 4 . A history hypertensive encephalopathy , unstable angina , transient ischemic attack , MI , type revascularization procedure within last 6 month 5 . Heart failure , second thirddegree heart block , significant arrhythmia valvular heart disease 6 . Significant cardiovascular , cerebrovascular , renal , gastrointestinal , hematologic disease , discretion investigator 7 . Creatinine clearance &lt; 20mL/min Renal artery stenosis , Renal Transplantation , Patients one kidney 8 . Evidence liver disease indicate alanine transaminase ( ALT ) aspartate transaminase ( AST ) and/or total bilirubin ≥ 3 × upper limit normal ( ULN ) 9 . Hyperkalemia ( &gt; 5.5mmol/L ) 10 . Patients sodium depletion correct Patients fluid depletion correct 11 . Chronic inflammation 12 . Patients severe eyerelated disorder ( Retinal bleeding within 6 month , Blindness , Hypertension complication Retinal microaneurysms ) 13 . Diabetes mellitus 14 . Hematologic/oncologic , neurologic psychiatric disease 15 . Females pregnant , breastfeeding , plan pregnancy childbearing potential 16 . Contraindications amlodipine , losartan , olmesartan medoxomil , ARBs 17 . With known allergic reaction , lack response contraindication Angiotensin II receptor antagonists 18 . Mean DBP &gt; 110 mmHg 19 . Patients take antihyperlipidemic agent within 30 day 20 . Subject participate clinical trial within last one month 21 . Any subject unable cooperate protocol requirement followup procedure medical condition eligible enter investigator ' discretion</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>